Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients

Yanan Zhao, Yoji Nagasaki, Padmaja Paderu, Michele W. Sugrue, Helen L. Leather, John R. Wingard, David S. Perlin

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

One critical factor impeding successful management of invasive aspergillosis (IA) is the lack of reliable biomarkers to assess therapeutic response. We hypothesized that changes in certain host biomarkers reflect the nature of infection status and disease progression. Upon primary IA diagnosis, these disease status biomarkers can be monitored to track response to antifungal therapy and provide early markers that prognosticate likelihood of response. Herein, we analyzed serum levels of three prominent host disease status biomarkers C-reactive protein (CRP), haptoglobin (Hp), and annexin A1 (ANXA1) in IA patients during antifungal therapy. A total of 81 serial serum samples were collected at five or six different time points relative to IA diagnosis from 15 probable IA patients (10 acute leukemia [AL] and five hematopoietic stem cell transplantation [HSCT]). Of note, different biomarker profiles were observed in AL and HSCT patients, as not only levels of markers were significantly lower in HSCT patients but also more prominent interconnections among markers were observed in AL patients. Using a composite evaluation, patients were categorized as responders, nonresponders, and stable cases at last specimen. For AL responders, typical biomarker profiles were high initially but rapidly decreased for CRP and Hp post antifungal therapy, while low initial ANXA1 values were restored to normal levels after treatment. In contrast, CRP and Hp were persistently elevated whilst ANXA1 remained low throughout therapy in AL non-responders. As a pilot proof-of-concept study, our work demonstrates the great potential of using host biomarkers to monitor early therapeutic response in leukemia patients.

LanguageEnglish
Pages38-44
Number of pages7
JournalMedical mycology
Volume57
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Aspergillosis
Biomarkers
Leukemia
Haptoglobins
Hematopoietic Stem Cell Transplantation
Annexin A1
C-Reactive Protein
Therapeutics
Annexins
Serum
Disease Progression
Infection

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. / Zhao, Yanan; Nagasaki, Yoji; Paderu, Padmaja; Sugrue, Michele W.; Leather, Helen L.; Wingard, John R.; Perlin, David S.

In: Medical mycology, Vol. 57, No. 1, 01.01.2019, p. 38-44.

Research output: Contribution to journalArticle

Zhao, Yanan ; Nagasaki, Yoji ; Paderu, Padmaja ; Sugrue, Michele W. ; Leather, Helen L. ; Wingard, John R. ; Perlin, David S. / Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. In: Medical mycology. 2019 ; Vol. 57, No. 1. pp. 38-44.
@article{b7e3d8ff20b048fd806b1b845a205190,
title = "Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients",
abstract = "One critical factor impeding successful management of invasive aspergillosis (IA) is the lack of reliable biomarkers to assess therapeutic response. We hypothesized that changes in certain host biomarkers reflect the nature of infection status and disease progression. Upon primary IA diagnosis, these disease status biomarkers can be monitored to track response to antifungal therapy and provide early markers that prognosticate likelihood of response. Herein, we analyzed serum levels of three prominent host disease status biomarkers C-reactive protein (CRP), haptoglobin (Hp), and annexin A1 (ANXA1) in IA patients during antifungal therapy. A total of 81 serial serum samples were collected at five or six different time points relative to IA diagnosis from 15 probable IA patients (10 acute leukemia [AL] and five hematopoietic stem cell transplantation [HSCT]). Of note, different biomarker profiles were observed in AL and HSCT patients, as not only levels of markers were significantly lower in HSCT patients but also more prominent interconnections among markers were observed in AL patients. Using a composite evaluation, patients were categorized as responders, nonresponders, and stable cases at last specimen. For AL responders, typical biomarker profiles were high initially but rapidly decreased for CRP and Hp post antifungal therapy, while low initial ANXA1 values were restored to normal levels after treatment. In contrast, CRP and Hp were persistently elevated whilst ANXA1 remained low throughout therapy in AL non-responders. As a pilot proof-of-concept study, our work demonstrates the great potential of using host biomarkers to monitor early therapeutic response in leukemia patients.",
author = "Yanan Zhao and Yoji Nagasaki and Padmaja Paderu and Sugrue, {Michele W.} and Leather, {Helen L.} and Wingard, {John R.} and Perlin, {David S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/mmy/myx164",
language = "English",
volume = "57",
pages = "38--44",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients

AU - Zhao, Yanan

AU - Nagasaki, Yoji

AU - Paderu, Padmaja

AU - Sugrue, Michele W.

AU - Leather, Helen L.

AU - Wingard, John R.

AU - Perlin, David S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - One critical factor impeding successful management of invasive aspergillosis (IA) is the lack of reliable biomarkers to assess therapeutic response. We hypothesized that changes in certain host biomarkers reflect the nature of infection status and disease progression. Upon primary IA diagnosis, these disease status biomarkers can be monitored to track response to antifungal therapy and provide early markers that prognosticate likelihood of response. Herein, we analyzed serum levels of three prominent host disease status biomarkers C-reactive protein (CRP), haptoglobin (Hp), and annexin A1 (ANXA1) in IA patients during antifungal therapy. A total of 81 serial serum samples were collected at five or six different time points relative to IA diagnosis from 15 probable IA patients (10 acute leukemia [AL] and five hematopoietic stem cell transplantation [HSCT]). Of note, different biomarker profiles were observed in AL and HSCT patients, as not only levels of markers were significantly lower in HSCT patients but also more prominent interconnections among markers were observed in AL patients. Using a composite evaluation, patients were categorized as responders, nonresponders, and stable cases at last specimen. For AL responders, typical biomarker profiles were high initially but rapidly decreased for CRP and Hp post antifungal therapy, while low initial ANXA1 values were restored to normal levels after treatment. In contrast, CRP and Hp were persistently elevated whilst ANXA1 remained low throughout therapy in AL non-responders. As a pilot proof-of-concept study, our work demonstrates the great potential of using host biomarkers to monitor early therapeutic response in leukemia patients.

AB - One critical factor impeding successful management of invasive aspergillosis (IA) is the lack of reliable biomarkers to assess therapeutic response. We hypothesized that changes in certain host biomarkers reflect the nature of infection status and disease progression. Upon primary IA diagnosis, these disease status biomarkers can be monitored to track response to antifungal therapy and provide early markers that prognosticate likelihood of response. Herein, we analyzed serum levels of three prominent host disease status biomarkers C-reactive protein (CRP), haptoglobin (Hp), and annexin A1 (ANXA1) in IA patients during antifungal therapy. A total of 81 serial serum samples were collected at five or six different time points relative to IA diagnosis from 15 probable IA patients (10 acute leukemia [AL] and five hematopoietic stem cell transplantation [HSCT]). Of note, different biomarker profiles were observed in AL and HSCT patients, as not only levels of markers were significantly lower in HSCT patients but also more prominent interconnections among markers were observed in AL patients. Using a composite evaluation, patients were categorized as responders, nonresponders, and stable cases at last specimen. For AL responders, typical biomarker profiles were high initially but rapidly decreased for CRP and Hp post antifungal therapy, while low initial ANXA1 values were restored to normal levels after treatment. In contrast, CRP and Hp were persistently elevated whilst ANXA1 remained low throughout therapy in AL non-responders. As a pilot proof-of-concept study, our work demonstrates the great potential of using host biomarkers to monitor early therapeutic response in leukemia patients.

UR - http://www.scopus.com/inward/record.url?scp=85055139794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055139794&partnerID=8YFLogxK

U2 - 10.1093/mmy/myx164

DO - 10.1093/mmy/myx164

M3 - Article

VL - 57

SP - 38

EP - 44

JO - Medical Mycology

T2 - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 1

ER -